Complete Response Demonstrated by [11C]methionine-PET Imaging of a Patient With Squamous-cell Carcinoma of the Tongue Treated With Chemotherapy, Immunotherapy and Methionine Restriction Without Radiation or Surgery: A Potential New Low-toxicity Treatment Paradigm for a Recalcitrant Disease
5 affiliations
- 1AntiCancer Inc., San Diego, CA, U.S.A.
- 2Department of Surgery, University of California, San Diego, CA, U.S.A.
- 3Department of Medical Oncology, Showa Medical University, Graduate School of Medicine, Tokyo, Japan
- 4Utsunomiya Central Clinic, Utsunomiya, Japan
- 5San Diego Oncology Medical Clinic, San Diego, CA, U.S.A.
Abstract
Background/Aim: Head and neck squamous-cell carcinoma (HNSCC) is associated with substantial morbidity. Treatment of locally-advanced disease commonly involves surgery, radiotherapy, and systemic therapy, which may result in functional impairment and treatment-related toxicity. Methionine addiction, known as the Hoffman effect, is a metabolic hallmark of cancer that is targeted by methionine restriction. We report here a patient with locally-advanced HPV-positive squamous-cell carcinoma of the tongue who achieved a complete response following chemotherapy combined with methionine restriction and subsequent immunotherapy, without surgery or radiotherapy.
Case Report: A 58-year-old man was diagnosed with HPV-positive squamous-cell carcinoma arising from the base of the tongue with extensive cervical lymph-node involvement (cT1N3M0). The patient elected to avoid surgery and radiotherapy because of concerns regarding functional impairment and disfigurement. Treatment consisted of seven cycles of docetaxel, cisplatinum, and 5-fluorouracil combined with a low-methionine diet and oral recombinant methioninase (o-rMETase). Pembrolizumab was initiated during the fifth chemotherapy cycle and continued as maintenance therapy. The cervical tumor rapidly regressed and became clinically undetectable after the initial treatment cycles. Follow-up [11C]methionine-PET/CT and [18F]FDG-PET/CT demonstrated no evidence of active disease, consistent with a complete response. The patient remains clinically well without evidence of recurrence and continues pembrolizumab therapy and methionine restriction.
Conclusion: The present case demonstrates a complete clinical and metabolic response in a patient with locally-advanced HPV-positive tongue squamous-cell carcinoma treated with combination chemotherapy, methionine restriction, and pembrolizumab without surgery or radiotherapy. Although the present findings suggest that methionine restriction may have potential as an adjunct to systemic treatment in HNSCC, additional case series and prospective clinical studies are required to determine the efficacy, safety, and generalizability of this therapeutic approach.
Related
- Cysteine reduction rather than methionine restriction promotes immunometabolic fitness to confer survival benefit in aging
- Efficacy and safety of narlumosbart in combination with stereotactic body radiation therapy followed by first-line chemotherapy combined with immunotherapy in advanced driver gene-negative non-small cell lung cancer patients with bone metastases: a phase II, single-arm, single-centre clinical trial protocol
- Immunotherapy plus chemotherapy versus immunotherapy alone in esophageal cancer: a real-world pharmacovigilance analysis of safety signals and fatal outcomes
- Analysis of Laryngoscopic Image Differences in Different Responses to Neoadjuvant Immunotherapy Combined With Chemotherapy in Locally Advanced Hypopharyngeal Carcinoma.
- Evaluation of the efficacy and safety of different cycles of neoadjuvant chemotherapy combined with immunotherapy in locally advanced esophageal squamous cell carcinoma: a multi-center, real-world study.
BibTeX
@article{ishiguro2026complete,
title = {{Complete Response Demonstrated by [11C]methionine-PET Imaging of a Patient With Squamous-cell Carcinoma of the Tongue Treated With Chemotherapy, Immunotherapy and Methionine Restriction Without Radiation or Surgery: A Potential New Low-toxicity Treatment Paradigm for a Recalcitrant Disease}},
author = {TOMOYUKI ISHIGURO and TOSHIHIKO SATO and QINGHONG HAN and SHUKUAN LI and YUTA MIYASHI and BYUNG MO KANG and S.Y. THOMAS SONG and TAKUYA TSUNODA and ROBERT M. HOFFMAN},
journal = {In Vivo},
year = {2026},
month = oct,
doi = {10.21873/invivo.14526},
url = {https://doi.org/10.21873/invivo.14526},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Complete Response Demonstrated by [11C]methionine-PET Imaging of a Patient With Squamous-cell Carcinoma of the Tongue Treated With Chemotherapy, Immunotherapy and Methionine Restriction Without Radiation or Surgery: A Potential New Low-toxicity Treatment Paradigm for a Recalcitrant Disease
AU - TOMOYUKI ISHIGURO
AU - TOSHIHIKO SATO
AU - QINGHONG HAN
AU - SHUKUAN LI
AU - YUTA MIYASHI
AU - BYUNG MO KANG
AU - S.Y. THOMAS SONG
AU - TAKUYA TSUNODA
AU - ROBERT M. HOFFMAN
PY - 2026
DA - 2026/10/29
JO - In Vivo
DO - 10.21873/invivo.14526
UR - https://doi.org/10.21873/invivo.14526
AB - Background/Aim: Head and neck squamous-cell carcinoma (HNSCC) is associated with substantial morbidity. Treatment of locally-advanced disease commonly involves surgery, radiotherapy, and systemic therapy, which may result in functional impairment and treatment-related toxicity. Methionine addiction, known as the Hoffman effect, is a metabolic hallmark of cancer that is targeted by methionine restriction. We report here a patient with locally-advanced HPV-positive squamous-cell carcinoma of the tongue who achieved a complete response following chemotherapy combined with methionine restriction and subsequent immunotherapy, without surgery or radiotherapy. Case Report: A 58-year-old man was diagnosed with HPV-positive squamous-cell carcinoma arising from the base of the tongue with extensive cervical lymph-node involvement (cT1N3M0). The patient elected to avoid surgery and radiotherapy because of concerns regarding functional impairment and disfigurement. Treatment consisted of seven cycles of docetaxel, cisplatinum, and 5-fluorouracil combined with a low-methionine diet and oral recombinant methioninase (o-rMETase). Pembrolizumab was initiated during the fifth chemotherapy cycle and continued as maintenance therapy. The cervical tumor rapidly regressed and became clinically undetectable after the initial treatment cycles. Follow-up [11C]methionine-PET/CT and [18F]FDG-PET/CT demonstrated no evidence of active disease, consistent with a complete response. The patient remains clinically well without evidence of recurrence and continues pembrolizumab therapy and methionine restriction. Conclusion: The present case demonstrates a complete clinical and metabolic response in a patient with locally-advanced HPV-positive tongue squamous-cell carcinoma treated with combination chemotherapy, methionine restriction, and pembrolizumab without surgery or radiotherapy. Although the present findings suggest that methionine restriction may have potential as an adjunct to systemic treatment in HNSCC, additional case series and prospective clinical studies are required to determine the efficacy, safety, and generalizability of this therapeutic approach.
SN - 0258-851X
SN - 1791-7549
ER -